









市场行情
/
股票
/
nasdaq-trvi
/

Trevi Therapeutics Inc

TRVI

12.850USD

-0.120-0.93%

收盘 12/26, 16:00（美东）报价延迟15分钟

1.65B总市值

亏损市盈率 TTM



Trevi Therapeutics Inc

12.850

-0.120-0.93%

概览公司财务分析

概览

公司

财务

分析

关于 Trevi Therapeutics Inc 公司

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Trevi Therapeutics Inc简介



公司代码TRVI

公司名称Trevi Therapeutics Inc

上市日期May 07, 2019

CEOGood (Jennifer L)

员工数量26

证券类型Ordinary Share

年结日May 07

公司地址195 Church Street

城市NEW HAVEN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编06510

电话12033042499

网址https://www.trevitherapeutics.com/

公司代码TRVI

上市日期May 07, 2019

CEOGood (Jennifer L)

Trevi Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. David P. Meeker, M.D.

Independent Chairman of the Board

352.49K

Dr. Thomas R. Sciascia, M.D.

Co-Founder, Chief Scientific Officer

214.43K

Ms. Jennifer L. Good

President, Chief Executive Officer, Director

213.31K

Dr. Farrell Simon, Pharm.D.

Chief Commercial Officer

76.90K

+68.46%

Ms. Anne M. Vanlent

Independent Director

25.98K

Mr. Michael Thomas (Mike) Heffernan

Independent Director

6.35K

Dr. James V. (Jim) Cassella, Ph.D.

Chief Development Officer

Mr. Dominick C. Colangelo

Independent Director

Mr. Edward T. Mathers

Independent Director

Jonathan Carlson

IR Contact Officer

名称

名称/职务

职务

持股

持股变动

Dr. David P. Meeker, M.D.

Independent Chairman of the Board

352.49K

Dr. Thomas R. Sciascia, M.D.

Co-Founder, Chief Scientific Officer

214.43K

Ms. Jennifer L. Good

President, Chief Executive Officer, Director

213.31K

Dr. Farrell Simon, Pharm.D.

Chief Commercial Officer

76.90K

+68.46%

Ms. Anne M. Vanlent

Independent Director

25.98K

Mr. Michael Thomas (Mike) Heffernan

Independent Director

6.35K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

New Enterprise Associates (NEA)

10.31%

Frazier Life Sciences Management, L.P.

8.00%

Rubric Capital Management LP

6.65%

BlackRock Institutional Trust Company, N.A.

5.75%

The Vanguard Group, Inc.

4.53%

其他

64.76%

持股股东

占比

New Enterprise Associates (NEA)

10.31%

Frazier Life Sciences Management, L.P.

8.00%

Rubric Capital Management LP

6.65%

BlackRock Institutional Trust Company, N.A.

5.75%

The Vanguard Group, Inc.

4.53%

其他

64.76%

股东类型

持股股东

占比

Investment Advisor

28.04%

Investment Advisor/Hedge Fund

24.51%

Venture Capital

17.14%

Hedge Fund

16.47%

Private Equity

10.58%

Research Firm

5.74%

Individual Investor

0.76%

Pension Fund

0.37%

Bank and Trust

0.27%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

272

116.14M

95.37%

+14.43M

2025Q2

232

94.28M

77.42%

+5.93M

2025Q1

226

89.66M

76.74%

+2.50M

2024Q4

177

80.67M

91.74%

+11.34M

2024Q3

156

59.14M

78.18%

-6.31M

2024Q2

148

56.93M

80.80%

-4.85M

2024Q1

147

52.57M

76.38%

-8.69M

2023Q4

131

54.54M

85.48%

-544.63K

2023Q3

124

54.64M

88.55%

-1.52M

2023Q2

115

54.75M

93.54%

+3.66M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

New Enterprise Associates (NEA)

11.37M

9.34%

-1.85M

-14.01%

Aug 11, 2025

Frazier Life Sciences Management, L.P.

10.26M

8.42%

Jun 30, 2025

Rubric Capital Management LP

8.53M

7.01%

+3.99M

+87.99%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.65M

4.64%

+1.10M

+24.11%

Jun 30, 2025

The Vanguard Group, Inc.

5.32M

4.37%

+1.48M

+38.53%

Jun 30, 2025

Vivo Capital, LLC

4.49M

3.69%

+1.00M

+28.67%

Jun 30, 2025

Marshall Wace LLP

2.48M

2.03%

-76.31K

-2.99%

Jun 30, 2025

AllianceBernstein L.P.

4.28M

3.52%

+4.26M

+19064.53%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.91%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.36%

Invesco Dorsey Wright Healthcare Momentum ETF

1.3%

ALPS Medical Breakthroughs ETF

0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

0.54%

Optimize Strategy Index ETF

0.37%

Vanguard US Momentum Factor ETF

0.22%

iShares Micro-Cap ETF

0.2%

Vanguard US Minimum Volatility ETF

0.18%

ProShares Ultra Nasdaq Biotechnology

0.14%

State Street SPDR S&P Pharmaceuticals ETF

占比1.91%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.36%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.3%

ALPS Medical Breakthroughs ETF

占比0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.54%

Optimize Strategy Index ETF

占比0.37%

Vanguard US Momentum Factor ETF

占比0.22%

iShares Micro-Cap ETF

占比0.2%

Vanguard US Minimum Volatility ETF

占比0.18%

ProShares Ultra Nasdaq Biotechnology

占比0.14%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Trevi Therapeutics Inc的前五大股东是谁？



Trevi Therapeutics Inc 的前五大股东如下：
New Enterprise Associates (NEA)持有股份：11.37M，占总股份比例：9.34%。
Frazier Life Sciences Management, L.P.持有股份：10.26M，占总股份比例：8.42%。
Rubric Capital Management LP持有股份：8.53M，占总股份比例：7.01%。
BlackRock Institutional Trust Company, N.A.持有股份：5.65M，占总股份比例：4.64%。
The Vanguard Group, Inc.持有股份：5.32M，占总股份比例：4.37%。